To accelerate innovation in the health and medical fields, the USPTO announced a fifth extension of its Cancer Immunotherapy Pilot Program. The program permits patent applications pertaining to cancer immunotherapy to be advanced out of turn for examination and reviewed earlier (accorded special status).
Petitions requesting participation in the pilot program that are compliant with the program’s requirements and are filed on or before January 31, 2023, will be accepted. All parameters will remain the same as in the original pilot through the January 31, 2023, extension.
The Federal Register Notice is available here.
by Element IP
Element IP is a premier boutique intellectual property law firm. Created specifically to service the needs of users of the US patent system, our firm combines extensive experience in patent procurement, counselling, licensing, post-grant proceedings, and litigation with innovative technology and staffing solutions to provide clients with high quality work product in a cost-effective and efficient manner.